The Latest Breaking News from ZBH

The healthcare technology market is well-poised for long-term growth, thanks to the growing demand for medical devices, cutting-edge technologies, and changing patient care systems. Thus, it could be wise to buy fundamentally solid healthcare technology stocks Zimmer Biomet Holdings (ZBH), STERIS (STE), and Tactile Systems Technology (TCMD), which are revolutionizing…

While Zimmer Biomet has lagged behind the broader market over the past year, analysts continue to hold a moderately positive view on the stock's prospects.

The health-tech industry’s long-term growth is fueled by the growing need for cutting-edge technologies to address critical areas, as well as the demand for personalized medicine. Thus, it could be wise to invest in fundamentally solid health-tech stocks McKesson (MCK), Cardinal Health (CAH), and Zimmer Biomet (ZBH) poised for long-term…

The medical device sector is evolving, driven by rising demand for precision technology in diagnostics. Therefore, it could be ideal to buy fundamentally solid medical device stocks Stryker Corp (SYK), Axogen (AXGN), and Zimmer Biomet Holdings (ZBH), which look poised for substantial growth. Read more….

Zimmer Biomet Holdings is expected to release its third-quarter earnings later this month, and analysts expect a single-digit earnings growth.

STERIS has underperformed the S&P 500 over the past year, yet analysts remain moderately bullish about the stock’s potential.

Zimmer Biomet has underperformed the healthcare sector over the past year, yet analysts remain moderately bullish about the stock’s prospects.

The medtech industry’s long-term growth is fueled by growing demand for medical devices, adoption of cutting-edge technologies, and improved efficiency. Thus, it could be ideal to buy fundamentally solid medtech stocks Baxter International (BAX), Zimmer Biomet Holdings (ZBH), and Embecta (EMBC) poised for substantial growth. Keep reading.

Despite Zimmer Biomet underperforming the broader market over the past year, analysts remain moderately bullish on the stock’s prospects.

Zimmer Biomet will release its second-quarter earnings next month, and analysts anticipate a single-digit profit growth.

Investing in oversold stocks can be a potentially profitable strategy for investors who are willing to take calculated risks and have a long-term perspective. Amid this backdrop, investors could consider buying fundamentally strong oversold stocks Comcast (CMCSA), Northrop Grumman (NOC), and Zimmer Biomet Holdings (ZBH) with an RSI below 30.…